• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Adding Fabrication Capabilities: Additive Manufacturing for Production Parts

    Delivering the Goods: The Evolving World of Combination Products

    Anxious Undertones: The 2019 Year in Review

    From Art to Science: The Changing Face of Extrusion

    Exact Science: A Micromolding Roundtable
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    FDA OKs Roche's Nasal Swab MRSA Test

    Philips & Paige to Deliver Clinical-Grade AI Applications to Pathology Labs

    Eye Test for Parkinson's Gains Breakthrough Designation

    Biomerics Forms New Business Unit

    J&J's New Monofocal IOL for Cataract Patients with Astigmatism
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Adding Fabrication Capabilities: Additive Manufacturing for Production Parts

    Delivering the Goods: The Evolving World of Combination Products

    Anxious Undertones: The 2019 Year in Review

    From Art to Science: The Changing Face of Extrusion

    Exact Science: A Micromolding Roundtable
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    From Genome Sequencing to the World’s First Portable MRI

    An Update on Digital Health

    ‘If You’re Reading This, You Need to Be at This Meeting’

    Five Steps for Succeeding Globally in Medtech

    Unlocking Market Doors with Real-World Evidence
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Eurofins Medical Device Testing

    Pulse Systems

    Nelson Laboratories LLC

    FUTEK Advanced Sensor Technology Inc.

    Zeus
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Understanding Key Processes for Mixing APIs with Silicone

    How to Minimize Color Variations in Your Medical Device

    Don’t Touch: Gesture Tech Is Reshaping How We Interact with Devices

    Revenue-Based Financing: A New Form of Growth Capital

    Pre-Filled Safety Syringes and the Self-Administration Trend
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    IQMS

    Command Medical Products Inc.

    Carclo Technical Plastics

    Marox Corporation

    Pulse Systems
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    PAVmed Announces PortIO Breakthrough

    Implantable intraosseous vascular access device achieves unprecedented maintenance-free implant duration of over 60 days in pre-clinical testing.

    Related CONTENT
    • MDR Insight: How to Strategize for CER Success
    • Insulet Partners With Samsung to Deliver Galaxy Smartphone-Controlled Insulin Pump Delivery System
    • Insulet’s Omnipod DASH Insulin Management System Receives ISO 27001 Certification
    • Orchestra BioMed Appoints Chief Financial Officer
    • BMP Medical Opens New Plastics Manufacturing Facility
    Globe Newswire04.24.19
    PAVmed Inc., a highly differentiated, multiproduct medical device company, announced that its PortIO Intraosseous Infusion System, which consists of an implantable intraosseous vascular access device and insertion kit, achieved a maintenance-free implant duration of over 60 days in pre-clinical animal testing.
     
    Former President of the Society of Interventional Radiology (SIR), Timothy P. Murphy, M.D., described this announcement as “a truly groundbreaking accomplishment in the field of vascular access which, if replicated in clinical practice, would represent one of the most important advances in long-term vascular access that I have seen during my career. All other vascular access devices, whether short, medium or long-term are limited by the need for regular maintenance with flushes which are labor intensive, costly and interfere with a patient’s activity.”
     
    “Improper flushing techniques and other factors can result in serious or even deadly complications, including bloodstream infections, air embolism and life-threatening blood clotting reactions to the drug Heparin used in flushes (Heparin Induced Thrombocytopenia or HIT),” Murphy added. “If this maintenance-free implant duration is preserved or exceeded through regulatory clearance and clinical launch, PortIO will provide significant benefits to a multitude of patients and the healthcare system as a whole – particularly those patients with poor venous access, those on, or expected to need, kidney dialysis and those with known adverse reactions to Heparin.”
     
    PAVmed recently completed a series of 7-day PortIO implants as part of a GLP animal study requested by the U.S. Food and Drug Administration (FDA). In parallel with this GLP study, it also performed a long-term pilot study to assess PortIO function and patency for up to 60 days. PortIO devices were used to infuse antibiotics, saline, albumin and blood at various intervals and over various implant durations. The device with the longest implant duration was simply left in place, untouched, with no infusions or flushes for a period of 62 days following implantation. Prior to removal, it’s function and patency was confirmed by injecting intravenous contrast material and visualizing brisk flow into the bone marrow and central veins.

    There was no evidence of clots, bony ingrowth or infection in any device or implant site.
     
    “The results of this pilot study are truly unprecedented,” said Lishan Aklog M.D., PAVmed’s chairman and CEO. “Although, for many decades, physicians have used the intraosseous route to infuse fluids, medications and other substances into patients through the bone marrow instead of through a vein, existing intraosseous devices protrude through the skin and can only be used for 24 hours or less. PortIO is the first implantable intraosseous device designed for long-term use and to eliminate many of the shortcomings of existing vascular access devices, including the need for regular maintenance. All long-term vascular access devices, including peripherally inserted central catheters (PICC), tunneled central venous catheters and implantable venous ports, require regular flushes by a skilled healthcare professional to prevent them from clotting."
     
    “We are gratified that these results validate our initial thesis that the fundamental biologic differences between bone marrow and the blood in veins would allow an innovatively designed implantable intraosseous port to remain patent and functioning over the long-term, without the need for flushes or other maintenance," Aklog said. "We are confident, based on the underlying biologic processes, that these pilot results will be replicated over longer implant durations and in upcoming human clinical studies. The over 60-day maintenance-free implant duration achieved already covers one of the most common indications for long-term vascular access—long-term intravenous antibiotics courses, which typically last four to eight weeks.”
     
    PortIO continues to advance through the FDA de novo pathway as it seeks an initial seven-day implant duration indication for use. The data from the recently completed GLP animal study will be submitted to the FDA once pathologic analysis of the implant sites is completed in the coming weeks. Based on this encouraging long-term preclinical data, PAVmed is planning to initiate a long-term (90-day implant duration) first-in-human series in Colombia, South America, in Q2-2019. It also intends to fulfill the likely FDA request for human clinical data to support its de novo application with a small short-term clinical safety study in New Zealand. Both studies will target the same patient population, namely patients with poor veins or the need to preserve veins for future dialysis. CE Mark submission is scheduled for Q2-2019 and the company continues to explore potential strategic partnerships, including acquisition of PortIO.
     
    The PortIO Intraosseous Infusion System consists of an implantable intraosseous vascular access device and insertion kit. Instead of a catheter located in a vein, it has a short extension from the device, which a physician inserts into a bone, leaving the device to reside completely beneath the skin. This allows direct access to the bone marrow, which is a well-established route for the delivery of medications, fluids and other substances. PortIO can be inserted and removed near-percutaneously without requiring a surgical pocket or significant dissection and does not require confirmation of the position of the tip by x-ray or other means. Once in place, the device can be accessed by the nurse through the skin using the same techniques as existing implantable ports. PortIO addresses known limitations of existing long-term vascular access devices which, in addition to the need for regular maintenance with flushes, include occlusion from blood clots, blood stream infections and difficult or impossible insertion in patients with poor veins. PortIO’s addressable market opportunity is estimated to be at least $700 million based on short-term patients with poor veins and medium or long-term patients who would benefit from its advantages over existing devices. This estimate does not include a separate, possibly larger, market opportunity in patients with renal failure whose veins must be carefully preserved for future hemodialysis.
     
    PAVmed Inc. is a medical device company employing a unique business model designed to advance innovative products to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its five lead products provide groundbreaking approaches to carpal tunnel syndrome (CarpX), precancerous conditions of the esophagus (EsoCheck), vascular access (PortIO), pediatric ear infections (DisappEAR) and medical infusions (NextFlo). The company is also developing products in other areas, such as catheters and tissue ablation, while seeking to further expand its pipeline through engagements with clinician innovators and leading academic medical centers. 
    Related Searches
    • testing
    • u.s. food and drug administration
    • fda
    • surgical
    Related Knowledge Center
    • Cardiovascular
    Suggested For You
    FDA Takes Steps to Reduce Surgical Stapler Risks FDA Takes Steps to Reduce Surgical Stapler Risks
    Rhythmlink Announces Investment Partnership with New Heritage Rhythmlink Announces Investment Partnership with New Heritage
    Five-Year Data Released for Medtronic VenaSeal VeClose Extension Study Five-Year Data Released for Medtronic VenaSeal VeClose Extension Study
    FDA Halts Sale of Pelvic Mesh in U.S. FDA Halts Sale of Pelvic Mesh in U.S.
    PAVmed Subsidiary Lucid Diagnostics Launches Medical Advisory Board PAVmed Subsidiary Lucid Diagnostics Launches Medical Advisory Board
    FDA Warns Genomics Lab About Illegally Marketing Genetic Test FDA Warns Genomics Lab About Illegally Marketing Genetic Test
    COPD Device Receives FDA Breakthrough Device Designation COPD Device Receives FDA Breakthrough Device Designation
    A New, Tailored Review Framework for Artificial Intelligence-Based Devices A New, Tailored Review Framework for Artificial Intelligence-Based Devices
    Mike on Medtech: FDA Mike on Medtech: FDA's Material Evaluation
    Wearable Sensors Mimic Skin to Help Wound Healing Wearable Sensors Mimic Skin to Help Wound Healing
    FDA Aims to Prevent Shortages Following Sterilization Shutdowns FDA Aims to Prevent Shortages Following Sterilization Shutdowns
    FDA to Modernize Mammography Services and Improve Their Quality FDA to Modernize Mammography Services and Improve Their Quality
    FDA Warns J&J and Sientra for Breast Implant Compliance Failure FDA Warns J&J and Sientra for Breast Implant Compliance Failure
    FDA to Closely Examine Surgical Stapler Risks FDA to Closely Examine Surgical Stapler Risks
    Saranas Saranas' Early Bird Bleed Monitoring System Gains De Novo Clearance

    Related Breaking News

    • Cardiovascular | Patient Monitoring
      VivaLNK Wearable Sensor and Software Development Kit Receive CE Mark

      VivaLNK Wearable Sensor and Software Development Kit Receive CE Mark

      The reusable patch weighs only 7.5 grams.
      PRNewswire 12.03.19

    • Cardiovascular | Surgical
      CryoLife

      CryoLife's Thoraco-abdominal Stent Graft Gains CE Mark

      First off-the-shelf option with pre-cannulated inner branch technology.
      PR Newswire 12.03.19

    • Cardiovascular
      Concept Medical Granted CE Certification for its Sirolimus Coated MagicTouch Group of Products

      Concept Medical Granted CE Certification for its Sirolimus Coated MagicTouch Group of Products

      Company is now focused on marketing the products in Europe.
      Businesswire 11.25.19


    • Cardiovascular
      Bristol-Myers Squibb-Pfizer Alliance, Fitbit Partner to Address Gaps in Afib Detection

      Bristol-Myers Squibb-Pfizer Alliance, Fitbit Partner to Address Gaps in Afib Detection

      Companies are joining forces to develop atrial fibrillation educational content to help identify and support those at increased risk of stroke.
      Businesswire 11.25.19

    • Cardiovascular | Digital Health
      Biofourmis Partners with Novartis

      Biofourmis Partners with Novartis

      Teams up to offer digital therapeutics for patients with heart failure.
      Biofourmis 11.19.19

    • Cardiovascular
      First Patient in Middle East Treated With CSI

      First Patient in Middle East Treated With CSI's Peripheral Orbital Atherectomy Technology

      Introduction of Orbital Atherectomy expands treatment options for patients with peripheral artery disease.
      Business Wire 11.19.19


    • Cardiovascular | Materials | Tubing & Extrusion
      CVC Manufactured from Special Urethane Material that Becomes Softer in the Body

      CVC Manufactured from Special Urethane Material that Becomes Softer in the Body

      Optimized design of central venous catheters reduces risk of complications.
      Flexan 11.18.19

    • Cardiovascular | Digital Health | Patient Monitoring | Software & IT
      Preventive Healthcare via Apps

      Preventive Healthcare via Apps

      Prevention through digital helpers from Fraunhofer and partners.
      Fraunhofer-Gesellschaft 11.18.19

    • Cardiovascular | Contract Manufacturing | Materials | Tubing & Extrusion
      Freudenberg Medical Launches Wave of Product and Process Innovations

      Freudenberg Medical Launches Wave of Product and Process Innovations

      Among new innovations is Helix iMC, a new technology to continuously measure the inner geometry of silicone tubes.
      Freudenberg Medical 11.18.19


    • Cardiovascular | Neurological | Surgical
      Neural Networks Enable Autonomous Navigation of Catheters

      Neural Networks Enable Autonomous Navigation of Catheters

      AI support for endovascular stroke therapy.
      Fraunhofer-Gesellschaft 11.18.19

    • Cardiovascular
      PQ Bypass Receives Unconditional IDE Approval From FDA to Start TORUS SFA Stent Graft Study

      PQ Bypass Receives Unconditional IDE Approval From FDA to Start TORUS SFA Stent Graft Study

      TORUS-2 marks second Investigational Device Exemption approved for company in less than two years.
      Business Wire 11.15.19

    • Cardiovascular | Patient Monitoring | Software & IT
      FDA OKs Ultromics

      FDA OKs Ultromics' AI-Powered Decision Support System

      AI automates cardiac analysis helping earlier detection of cardiovascular disease, enabling clinicians to improve patient care and outcomes.
      PR Newswire 11.14.19

    • Cardiovascular
      THI’s Research Team Receives a Federal Grant

      THI’s Research Team Receives a Federal Grant

      Is developing a wireless and leadless pacemaker system.
      Texas Heart Institute 11.13.19

    • Cardiovascular
      Third-Party Evaluation Confirms Safety Profile of Philips Stellarex Low-Dose Drug-Coated Balloon

      Third-Party Evaluation Confirms Safety Profile of Philips Stellarex Low-Dose Drug-Coated Balloon

      Data show no difference in mortality between patients treated with the Philips Stellarex DCB and those treated with percutaneous angioplasty.
      Globe Newswire 11.11.19

    • Cardiovascular
      Study Shows Safety, Efficacy of Near Infrared Spectroscopy Imaging to Identify MACE Risk

      Study Shows Safety, Efficacy of Near Infrared Spectroscopy Imaging to Identify MACE Risk

      Trial identified both vulnerable patients and plaques that are at significantly higher risk for subsequent major adverse cardiac events.
      Business Wire 11.08.19


    Breaking News
    • FDA OKs Roche's Nasal Swab MRSA Test
    • Philips & Paige to Deliver Clinical-Grade AI Applications to Pathology Labs
    • Eye Test for Parkinson's Gains Breakthrough Designation
    • Biomerics Forms New Business Unit
    • J&J's New Monofocal IOL for Cataract Patients with Astigmatism
    View Breaking News >
    CURRENT ISSUE

    November/December 2019

    • Adding Fabrication Capabilities: Additive Manufacturing for Production Parts
    • Delivering the Goods: The Evolving World of Combination Products
    • Anxious Undertones: The 2019 Year in Review
    • View More >
    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    International Scientific Society Calls for Omega-3 Blood Testing in Future Research
    Pharmactive Affron Saffron May Help Relieve Depression Symptoms
    Warmer Temperatures Could Lead to Concerning Levels of Arsenic in Rice
    Coatings World

    Latest Breaking News From Coatings World

    Cristo Rey High School Educator Named 2019 Axalta All-Pro Teacher of the Year
    Michelman Makes United Way of Greater Cincinnati’s List of Top 25 Corporate Campaigns
    BCF: Coatings Industry Reports Record Improvement in Waste, Recycling, Accident Rates
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs Roche's Nasal Swab MRSA Test
    Philips & Paige to Deliver Clinical-Grade AI Applications to Pathology Labs
    Eye Test for Parkinson's Gains Breakthrough Designation
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Almac Awarded $1M BMGF Grant
    Vivera Pharma, Parexel Ink Clinical Services Agreement
    MedPharm Triples Capacity at RTP Site
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    WWP Wins Three NJPEC Awards
    Cat-Themed Beauty Collection to Launch in Japan
    Pantone Names Classic Blue the 2020 Color of the Year
    Happi

    Latest Breaking News From Happi

    Lip Lab Opening in Brooklyn
    Raining Rose Expands Exec Team
    Scott’s Sells Personal Care Production Site
    Ink World

    Latest Breaking News From Ink World

    ePac Flexible Packaging Expands into Asia Pacific Market
    Haney, HP Developing Sustainable Fashion Packaging for Heron Preston
    Addipel Moves to New HQ, Expands Production Facility
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    HP teams with Haney for sustainable packaging
    Tags & Labels Printing adds Heidelberg’s Versafire EP
    Austrian converter installs first Nilpeter press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Thrace to Relocate U.S. Capacity
    FiltXPO Speaker Line-Up Announced
    Nölken Incorporates Sustainable Wipes Packaging
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Orthofix Appoints New Spine Business Leader
    Viant to Halt EtO Sterilization at Michigan Plant by End of Year
    Synaptive Medical's Modus V Expands Into Spine Market
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    IDTechEx Show! Announces Graphene Award Winner
    OE-A Continues to Bring Future of Printed Electronics to CES 2020
    Avancis, Smit Thermal, HZB, CNRS, Solliace Team for Higher Efficiencies in CIGS

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.